Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

KMT5A-Mediated Methylation of IRF3 Promotes Tumor Progression through Immune Suppression

ABSTRACT: Lysine methylation is a critical post-translational modification (PTM) involved in diverse physiological and pathological processes. Interferon regulatory factor 3 (IRF3) plays a pivotal role in antitumor immunity; however, the regulatory mechanisms and functional impact of IRF3 methylation within the tumor microenvironment remain incompletely understood. This study demonstrates that monomethylation of IRF3 at lysine 193 (K193) suppresses its phosphorylation-dependent activation. Mass spectrometry-based protein interactome analysis identified lysine methyltransferase 5A (KMT5A) as the key enzyme responsible for IRF3 K193 monomethylation. In colorectal cancer (CRC), aberrantly high expression of KMT5A impaired in vivo antitumor immune responses. Mechanistically, KMT5A catalyzes IRF3 monomethylation at K193, which impedes IRF3 phosphorylation and subsequent activation, thereby suppressing the production of type I interferons (IFN-I). Collectively, these findings elucidate KMT5A-mediated IRF3 K193 methylation as a critical regulatory axis promoting tumor immune evasion and progression. Furthermore, IRF3 K193 methylation represents a promising therapeutic target for CRC intervention.

ORGANISM(S): Homo sapiens

PROVIDER: GSE312287 | GEO | 2025/12/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

KMT5A-Mediated Methylation of IRF3 Promotes Tumor Progression through Immune Suppression

Project description:KMT5A-Mediated Methylation of IRF3 Promotes Tumor Progression through Immune Suppression

| PRJNA1372776 | ENA

Transcriptomic analysis of KMT5A-knockout healthy volunteer peripheral blood CD8+ T cells under activated conditions

Project description:This study aims to investigate the role of Lysine Methyltransferase 5A (KMT5A, also known as SETD8) in CD8+ T cell biology. CD8+ T cells were isolated from healthy volunteer PBMCs using magnetic bead-based negative selection. Isolated cells were subjected to CRISPR-Cas9 mediated gene editing targeting KMT5A (KMT5A-KO group) or a non-targeting control guide RNA (control group, CTRL) via ribonucleoprotein (RNP) complex electroporation. Cells were harvested at 72 hours post-electroporation for RNA extraction. RNA sequencing (RNA-seq) libraries were constructed using the Illumina TruSeq Stranded mRNA kit and sequenced on an Illumina platform to generate paired-end reads. Transcriptome profiles of KMT5A-KO CD8+ T cells were compared to those of CTRL cells to identify differentially expressed genes (DEGs) and elucidate potential pathways regulated by KMT5A in this cell type.

2025-12-02 | GSE304753 | GEO

Identification of KMT5A regulated genes in prostate cancer

Project description:The methyltransferase, KMT5A, is suggested as an oncogene in prostate cancer but the mechanisms underlying its oncogenic properties are poorly understood. This study uncovers genes and cellular pathways which are regulated by KMT5A in LNCaP-AI cells, a model of androgen independence.

2023-05-26 | GSE233350 | GEO

Inhibition of FBP1 expression by KMT5A through TWIST1 methylation is one of the mechanisms leading to chemoresistance in breast cancer

Project description:Lysine methyltransferase 5A (KMT5A) is the sole mammalian enzyme known to catalyze the monomethylation of histone H4 lysine 20 (H4K20mel) and nonhistone proteins such as p53, which are involved in the occurrence and progression of many cancers. Our study aimed to determine the function of KMT5A in inducing docetaxel resistance in patients with breast carcinoma by evaluating glucose metabolism and the underlying mechanism involved. KMT5A is highly expressed in breast cancer cells; therefore, we examined the upregulation or downregulation of KMT5A-related proteins after KMT5A knockdown in breast cancer cells by TMT proteomics. Through differential protein expression and pathway enrichment analysis, the upregulated key gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1) was found. Loss of FBP1 expression is closely related to the development and prognosis of various tumors. A dual-luciferase reporter gene assay confirmed that KMT5A inhibited the expression of FBP1 and that overexpression of FBP1 could enhance the chemotherapeutic sensitivity to docetaxel through the suppression of KMT5A expression. The KMT5A inhibitor UNC0379 was used to verify that docetaxel resistance induced by KMT5A through the inhibition of FBP1 depended on the methylase activity of KMT5A. According to previous literature reports and the database interaction network structure, we found that KMT5A acts on the transcription factor TWIST1. Then, we verified that TWSIT1 promoted the expression of FBP1 by using dual-luciferase reporter gene experiments. Depending on its methylase activity, KMT5A can positively regulate glycolysis-mediated chemotherapy resistance by inhibiting the transcription of FBP1 in collaboration with TWIST1. KMT5A affects chemotherapy resistance by regulating the cell cycle, which represents another potential therapeutic target for KMT5A.

2024-04-20 | PXD051634 |

Histone H4 Lysine 20 Methylation Marks Genes Dynamically Regulated During Erythroid Maturation [CUT&Run_2]

Project description:We profiled H4K20 monomethylation and KMT5A during the well-characterized erythroid differentiation of human hematopoietic stem and progenitor cells.

2025-07-30 | GSE300158 | GEO

Direct lysine dimethylation of IRF3 by the methyltransferase SMYD3 attenuates antiviral innate immunity [II]

Project description:Interferon regulatory factor 3 (IRF3) is the key transcription factor in the type I IFN signaling pathway, whose activation is regulated by multiple posttranslational modifica_x0002_tions. Here, we identify SMYD3, a lysine methyltransferase, as a negative regulator of IRF3. SMYD3 interacts with IRF3 and catalyzes the dimethylation of IRF3 at lysine 39. This modification reduces IRF3 phosphorylation, dimerization, and subsequent nuclear translocation, leading to the inhibition of downstream type I interferon production. In addition, Smyd3-deficient mice are more resistant to RNA and DNA viral infections. Zebrafish lacking smyd3 or treated with the inhibitor BCI121 are also more resistant to viral infection. Our findings reveal a role for SMYD3 in the regulation of antiviral innate immunity and provide insight into a unique modulation of IRF3 that affects its activation.

2025-01-03 | GSE285750 | GEO

Direct lysine dimethylation of IRF3 by the methyltransferase SMYD3 attenuates antiviral innate immunity

2025-01-01 | GSE285658 | GEO

Identification of KMT5A regulated genes in prostate cancer

Project description:Identification of KMT5A regulated genes in prostate cancer

| PRJNA975927 | ENA

DNA hypermethylation encroachment at CpG island borders in cancer is predisposed by H3K4 monomethylation [WGBS_Mm]

Project description:The crosstalk between H3K4 monomethylation and DNA methylation has been receiving little attention to date. We investigated a mouse model harboring a loss-of-function mutation of lysine methyltransferase 2D (KMT2D), which catalyzes the monomethylation of lysine 4 on histone H3. We performed H3K4me1 ChIP-seq in spleen B cells with the wild type (WT) KMT2D as well as heterozygous (HET) and homozygous (HOM) chr15: 98,835,228 A>T KMT2D mutation. Alongside, using WGBS, we performed genome-wide DNA methylation profiling in spleen B cells with the WT KMT2D as well as HET and HOM chr15: 98,835,228 A>T KMT2D mutation.

2019-01-23 | GSE104781 | GEO

DNA hypermethylation encroachment at CpG island borders in cancer is predisposed by H3K4 monomethylation [ChIP-Seq]

2019-01-23 | GSE104533 | GEO